EAP of Apitegromab for Patients With Spinal Muscular Atrophy

Summary

The purpose of this expanded access program (EAP) is to provide access to apitegromab for eligible patients with spinal muscular atrophy (SMA) prior to approval by the local regulatory agency . A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications